Immune tolerance induction in patients with severe hemophilia A with inhibitors

Blood Research

Volumn 50, Issue 4, 2015, Pages 248-253

  Ryu, Ji Eun ^a   Park, Young Shil ^a   Yoo, Ki Young ^b   Lee, Kyoo Duck ^c   Choi, Yong Mook ^b  

^a Kyung Hee University College of Medicine   (South Korea)

^b Korea Hemophilia Foundation Clinic   (South Korea)

^c Health Insurance Review Agency   (South Korea)

Author keywords

Hemophilia A; Immune tolerance induction; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DRUG HALF LIFE; GENE MUTATION; GENOTYPE; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRON; NONSENSE MUTATION; TREATMENT DURATION;

EID: 84950996474     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2015.50.4.248     Document Type: Article

References (24)

1. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedicstatus of haemophilia patients with inhibitors. Haemophilia2007;13:606-12.
2. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E.International workshop on immune tolerance induction: consensusrecommendations. Haemophilia 2007;13(Suppl 1):1-22.
3. Matzinger P. Tolerance, danger, and the extended family. AnnuRev Immunol 1994;12:991-1045.
4. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. Thediagnosis and management of factor VIII and IX inhibitors: aguideline from the UK Haemophilia Centre Doctors' Organization(UKHCDO). Br J Haematol 2000;111:78-90.
5. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A,DiMichele DM. The use of factor VIII/von Willebrand factorconcentrate for immune tolerance induction in haemophilia Apatients with high-titre inhibitors: association of clinical outcomewith inhibitor epitope profile. Haemophilia 2008;14:295-302.
6. Hwang TJ. Annual report of Korea Hemophilia Foundation 2012.Seoul, Korea: Korea Hemophilia Foundation, 2012:22.
7. Brackmann HH, Gormsen J. Massive factor-VIII infusion inhaemophiliac with factor-VIII inhibitor, high responder. Lancet1977;2:933.
8. Auerswald G, Spranger T, Brackmann HH. The role of plasmaderivedfactor VIII/von Willebrand factor concentrates in thetreatment of hemophilia A patients. Haematologica 2003;88:EREP05.
9. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction inthe treatment of paediatric haemophilia A patients with factorVIII inhibitors. Haemophilia 2000;6:150-7.
10. Hay CR, DiMichele DM; International Immune Tolerance Study.The principal results of the International Immune ToleranceStudy: a randomized dose comparison. Blood 2012;119:1335-44.
11. Valentino LA, Kempton CL, Kruse-Jarres R, et al. US Guidelinesfor immune tolerance induction in patients with haemophilia aand inhibitors. Haemophilia 2015;21:559-67.
12. Mariani G, Ghirardini A, Bellocco R. Immune tolerance inhemophilia-principal results from the International Registry.Report of the factor VIII and IX Subcommittee. Thromb Haemost1994;72:155-8.
13. DiMichele DM, Kroner BL; North American Immune ToleranceStudy Group. The North American Immune Tolerance Registry:practices, outcomes, outcome predictors. Thromb Haemost2002;87:52-7.
14. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, PolackB. Immune tolerance induction with highly purified plasmaderivedfactor VIII containing von Willebrand factor in hemophiliaA patients with high-responding inhibitors. Haematologica2005;90:1288-90.
15. Kurth M, Puetz J, Kouides P, et al. The use of a single vonWillebrand factor-containing, plasma-derived FVIII product inhemophilia A immune tolerance induction: the US experience. JThromb Haemost 2011;9:2229-34.
16. Kurth MA, Dimichele D, Sexauer C, et al. Immune tolerancetherapy utilizing factor VIII/von Willebrand factor concentratein haemophilia A patients with high titre factor VIII inhibitors.Haemophilia 2008;14:50-5.
17. Gringeri A, Musso R, Mazzucconi MG, et al. Immune toleranceinduction with a high purity von Willebrand factor/VIII complexconcentrate in haemophilia A patients with inhibitors at high riskof a poor response. Haemophilia 2007;13:373-9.
18. Sukhu K, Keeling DM, Giangrande PL. Variation in inhibitorreactivity in acquired haemophilia A with different concentrates. Clin Lab Haematol 2000;22:287-90.
19. Gilles JG, Jacquemin MG, Saint-Remy JM. Factor VIII inhibitors.Thromb Haemost 1997;78:641-6.
20. Gensana M, Altisent C, Aznar JA, et al. Influence of vonWillebrand factor on the reactivity of human factor VIIIinhibitors with factor VIII. Haemophilia 2001;7:369-74.
21. Astermark J, Voorberg J, Lenk H, et al. Impact of inhibitor epitopeprofile on the neutralizing effect against plasma-derived andrecombinant factor VIII concentrates in vitro. Haemophilia2003;9:567-72.
22. Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Haemophilia A:effects of inhibitory antibodies on factor VIII functionalinteractions and approaches to prevent their action. Haemophilia2002;8:1-11.
23. Gringeri A, Musso R, Bernasconi S, et al. Immunotoleranceinduction (ITI) with high purity FVIII/VWF concentrates ininhibitors patients with a high risk of a poor response to ITI: Aprospective surveillance. J Thromb Haemost (ISTH Congresses Abstracts) 2005;3(Suppl):abst 207.
24. Kim CY, Lee KN, Park YS. The use of rituximab with immunetolerance induction therapy for hemophilia A with inhibitors.Clin Pediatr Hematol Oncol 2015;22:67-71.